Highlights
1 patent
About
DNA Correction and Genome-editing Platforms
Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy.
Emendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.
Identity
| Name | Emendo Biotherapeutics |
|---|---|
| Slug | emendo-biotherapeutics |
| Type / kind | startup |
| Crunchbase ID | emendo-biotherapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwP6S6ZoKDA |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by AnGes on Dec, 2020 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon Street 2, Ness Ziona, Israel |
Web & social
| Website | https://www.emendobio.com/ |
|---|---|
| https://www.linkedin.com/company/10443839 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
genome-editinggene-editingbiopharmaceuticalgenomics
Funding
| Total raised | $73.0M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}